Pnocyistis in dog.
Reading File
Finding Sources
Searching the Web
Pneumocystis carinii pneumonia dogs clinical signs diagnosis treatment
Searching PubMed
Pneumocystis carinii dog canine
Reading Web Page
https://cavalierhealth.org/pneumonia.htm
Reading Article
PMID: 42062104
Finding Sources
I now have comprehensive information to provide a thorough answer on Pneumocystosis in dogs. Let me compile this.
Pneumocystosis (Pneumocystis Pneumonia) in Dogs
What Is It?
Pneumocystosis is a pulmonary fungal infection caused by Pneumocystis carinii (the canine-specific species; humans are affected by P. jirovecii). Despite historically being classified as a protozoan, it is now firmly recognized as an atypical fungus. In dogs, the organism selectively colonizes and proliferates in the lower respiratory tract - settling in the alveoli, causing inflammation, alveolar-capillary blockage, impaired gas exchange, and pulmonary alveolar damage.
Breed Predisposition
This is one of the most important clinical features. Pneumocystosis in dogs is strongly breed-associated, occurring almost exclusively in two breeds with underlying immune deficiencies:
- Miniature Dachshunds - most commonly affected
- Cavalier King Charles Spaniels (CKCS) - second most common; well-documented predisposition
A 2017 meta-analysis of 43 published canine cases found 17 Miniature Dachshunds and 16 CKCS among confirmed cases. A 2026 review in Vet Clinics of North America confirms this breed-related immune deficit as a key predisposing factor.
Other breeds can be affected, but the infection is almost always associated with an underlying immunodeficiency - commonly immunoglobulin (antibody) deficiencies.
Pathogenesis
- Transmission is via airborne droplets from colonized hosts within the same species
- The organism settles in the alveoli and proliferates there
- This leads to: alveolar inflammation → capillary blockage → decreased gas exchange → pulmonary damage
- Normal healthy dogs can be colonized but resist disease; clinical infection requires immunosuppression or primary immunodeficiency
Clinical Signs
Affected dogs typically present with afebrile pneumonia (no fever, which helps distinguish from bacterial pneumonia). Common signs include:
| Sign | Notes |
|---|---|
| Tachypnea / dyspnea | Most consistent finding |
| Cough | Dry or productive |
| Cyanosis | Indicates severe hypoxia |
| Exercise intolerance | Often progressive |
| Inappetence / weight loss | Chronic cases |
| Acute syncopal episodes | Reported in severe CKCS cases |
| Secondary pulmonary hypertension | Can complicate severe/chronic cases |
A March 2025 case report described a 16-month-old CKCS presenting with progressive tachypnea, syncopal episodes, increased respiratory effort, and weight loss - all failing to respond to standard antibiotics and antifungals before a Pneumocystis diagnosis was made by PCR.
Diagnostics
Hematology/Serology:
- Leukocytosis may or may not be present (often absent given the afebrile nature)
- Serum immunoglobulin levels - evaluate for underlying immunodeficiency (IgA, IgM, IgG deficiencies)
Thoracic Radiography:
- Diffuse interstitial to alveolar infiltrates, typically bilateral
- May show consolidation
Definitive Diagnosis - sampling methods:
- Bronchoalveolar lavage (BAL) - traditionally the gold standard; cytology with methenamine silver (GMS) or Diff-Quik staining can reveal cysts
- PCR - increasingly the preferred method; can be performed on:
- BAL fluid
- Oropharyngeal swabs (less invasive; validated in recent reports)
- Tracheal wash specimens
Histopathology (post-mortem or biopsy):
- "Foamy" eosinophilic alveolar exudate with characteristic cysts on silver staining
- Confirms diagnosis in many older published cases
Treatment
Drug of choice: Trimethoprim-sulfonamide (TMP-SMZ)
- Same drug used in human Pneumocystis pneumonia
- Clinical signs resolved with this drug in the 2025 CKCS case report
- Combined with an anti-inflammatory (e.g., prednisolone) to reduce inflammatory response in the alveoli
Supportive care:
- Oxygen therapy (oxygen cage or nasal catheter at 40-60% FiO2 if hypoxemic)
- IV fluids if needed
- Treatment of secondary pulmonary hypertension if present
- Nebulization and coupage (pulmonary physiotherapy)
Duration: Treatment typically continues for at least 1 week beyond resolution of clinical signs; radiographic clearance should be confirmed.
Prognosis:
- Guarded to poor in severely immunocompromised dogs
- Dogs with concurrent systemic disease are significantly less likely to be discharged
- Early diagnosis and treatment in CKCS with primary immune deficiency carry a better prognosis
Key Differentials
Because dogs present with afebrile interstitial pneumonia that does not respond to antibiotics, always consider Pneumocystosis in Miniature Dachshunds and CKCS presenting this way. Other differentials include:
- Viral pneumonia
- Other fungal pneumonias (Aspergillus, Cryptococcus)
- Bacterial bronchopneumonia (usually febrile)
Summary Table
| Feature | Detail |
|---|---|
| Causative agent | Pneumocystis carinii (fungus) |
| Breeds at risk | Miniature Dachshund, Cavalier King Charles Spaniel |
| Predisposing factor | Primary immunodeficiency (Ig deficiency) |
| Key clinical sign | Afebrile, progressive dyspnea |
| Diagnosis | PCR (oropharyngeal swab or BAL), cytology/histopathology |
| Treatment | Trimethoprim-sulfonamide + anti-inflammatory + supportive care |
This is a shared conversation. Sign in to Orris to start your own chat.